Trial Condition(s):

Metastatic castration resistant prostate cancer (mCRPC)

EPIX, a study to gather more information about characteristics of patients and other factors which may contribute to survival over a long period of time in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with Radium-223 (Xofigo) (EPIX)

Bayer Identifier:

20977

ClinicalTrials.gov Identifier:

NCT04516161

EudraCT Number:

Not Available

Study Completed

Trial Purpose

In this observational study researchers want to gather more information about the characteristics of patients treated with Radium-223 (Xofigo) who had survived over a long period of time prostate cancer that had spread to other places in the body and keeps growing even when the amount of testosterone in the body is reduced to very low levels (metastatic castration-resistant prostate cancer, mCRPC). In addition researchers want to identify the factors which may contribute to survival over a long period of time in those patients. Radium-223 (Ra-223) is an alpha particle-emitting radioactive agent approved for the treatment of men with metastatic castration-resistant prostate cancer (mCRPC).

Inclusion Criteria
- Adult patients with documented diagnosis of mCRPC (≥18 years at diagnosis), and 
- Received Ra-223 as one of the therapies between Jan 1, 2013 and Jun 31, 2019 after diagnosis of mCRPC
Exclusion Criteria
- Patients involved in clinical trials

Trial Summary

Enrollment Goal
1180
Trial Dates
black-arrow
Phase
N/A
Could I receive a placebo?
No
Products
Xofigo (Radium-223 dichloride, BAY88-8223)
Accepts Healthy Volunteers
No

Where to Participate

Loading...
Locations
Status
LocationsStatus
Locations

Bayer Flatiron Xofigo Registry database

Whippany, United States, 07981

Status
Completed
 

Trial Design